Biotech CEO: Sarbanes-Oxley audits stand in way of IPO – The Business Journal
The biggest complaint businesses have about the law is the cost of complying with Section 404 ... Without product revenue, biotech companies on the public market are forced to ask investors to pay for SOX reporting rather than scientific research.”
Subscribe to LegalLaw247.Com Newsletter